Dexcom revealed the Dexcom G8 continuous glucose monitor (CGM) at its 2026 Investor Day. The G8 is half the size of the current Dexcom G7, sporting a more square shape and rounded corners. The adhesive patch also appears to be smaller, so it will take up less surface area on the body.
Dexcom G8 (right) is 50% smaller than the Dexcom G7 (left). (source: Dexcom)
Dexcom’s CEO, Jake Leach, said 15 days is now the standard for all of its CGMs moving forward, so we can assume the G8 will last 15 days plus with an additional 12 hour grace period like on the G7. Dexcom did not confirm age range, but it is likely to support ages 2 years and up.
The G8 incorporates technology that’s been in development for almost 20 years. With a reduction in the Mean Absolute Relative Difference (MARD) and outlier readings, this promises to be Dexcom’s most accurate CGM yet. What’s really exciting is the self-adapting technology in this device. This sensor will adapt to each user’s physiology throughout the 15 days to ensure continuous precision and reliability.
Slide from Dexcom’s Investor Day (source: Dexcom)
The G8 is expected to be submitted to the FDA for clearance in 2027, with plans to release it to consumers toward the end of 2027 or beginning of 2028.
Jake Leach also said the company is working on a multianalyte sensor that monitors potassium levels in addition to glucose—a CGPM. This could help people at risk of hyperkalemia, a condition where potassium builds up in the bloodstream, often due to reduced kidney function, and can potentially lead to serious heart complications. Today, potassium is typically measured through bloodwork, with no widely available at-home continuous monitoring option.
When asked by a reporter, Jake Leach said ketone monitoring is also planned to be part of the G8 platform, but not at launch. Abbot is working on its own dual ketone-glucose sensor built on the FreeStyle Libre 3 CGM form factor, so it will be the same size as two U.S. pennies stacked together.
All of this news right as the trusted G6 is phasing out! What do you think? Are you excited for the G8? Let us know in the comments.
This is a developing story.
Want more?
For the latest diabetes tech, join our free newsletter.
If you like our content and want more, join Diabetech All Access—unlocking exclusive Live Q&As, giveaways, stories and industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving.
Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a healthcare team before making changes to your treatment.